



UCB
News

Acquisition of own shares

Brussels (Belgium), 7 April 2017 – 20:00 (CEST) – regulated information

In application of article 207 of the Royal Decree executing the Companies Code, UCB SA/NV announces that on March 30, 2017, UCB SA/NV and 22 direct affiliates bought 52 055 and 83 122 UCB shares respectively (settlement date April 3, 2017), OTC from an affiliate, at a price of € 72.3487 per share, in view of deliveries of shares to employees within the framework of the Long Term Incentive Program of the UCB Group.

The highest independent bid price on Euronext Brussels on 30 March 2017 was € 72.70.

On 3 April 2017, after settlement of these transactions and the deliveries of these shares to employees, UCB SA/NV (taking into account the holdings of its affiliates) owned 6 671 138 UCB shares, which represent 3.43 % of the total number of shares issued by the company (194 505 658).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news